A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
After 40 years of failed promises, spider silk is finally in mass production. Kraig Biocraft is producing 10 metric tons monthly using genetically modified silkworms.
Four astronauts launch on Artemis II this April, flying around the Moon for the first time since 1972. Meet the crew breaking new ground 53 years later.
Zorevunersen cuts seizures by 91% in Dravet syndrome, a rare genetic childhood epilepsy. The first disease-modifying treatment targets SCN1A mutations—a precision medicine breakthrough.
A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
After 40 years of failed promises, spider silk is finally in mass production. Kraig Biocraft is producing 10 metric tons monthly using genetically modified silkworms.
Four astronauts launch on Artemis II this April, flying around the Moon for the first time since 1972. Meet the crew breaking new ground 53 years later.
Zorevunersen cuts seizures by 91% in Dravet syndrome, a rare genetic childhood epilepsy. The first disease-modifying treatment targets SCN1A mutations—a precision medicine breakthrough.
A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
After 40 years of failed promises, spider silk is finally in mass production. Kraig Biocraft is producing 10 metric tons monthly using genetically modified silkworms.
Four astronauts launch on Artemis II this April, flying around the Moon for the first time since 1972. Meet the crew breaking new ground 53 years later.
A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
After 40 years of failed promises, spider silk is finally in mass production. Kraig Biocraft is producing 10 metric tons monthly using genetically modified silkworms.
Four astronauts launch on Artemis II this April, flying around the Moon for the first time since 1972. Meet the crew breaking new ground 53 years later.
Zorevunersen cuts seizures by 91% in Dravet syndrome, a rare genetic childhood epilepsy. The first disease-modifying treatment targets SCN1A mutations—a precision medicine breakthrough.
A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
After 40 years of failed promises, spider silk is finally in mass production. Kraig Biocraft is producing 10 metric tons monthly using genetically modified silkworms.
Four astronauts launch on Artemis II this April, flying around the Moon for the first time since 1972. Meet the crew breaking new ground 53 years later.
A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
After 40 years of failed promises, spider silk is finally in mass production. Kraig Biocraft is producing 10 metric tons monthly using genetically modified silkworms.
Four astronauts launch on Artemis II this April, flying around the Moon for the first time since 1972. Meet the crew breaking new ground 53 years later.
Zorevunersen cuts seizures by 91% in Dravet syndrome, a rare genetic childhood epilepsy. The first disease-modifying treatment targets SCN1A mutations—a precision medicine breakthrough.
A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
After 40 years of failed promises, spider silk is finally in mass production. Kraig Biocraft is producing 10 metric tons monthly using genetically modified silkworms.
Four astronauts launch on Artemis II this April, flying around the Moon for the first time since 1972. Meet the crew breaking new ground 53 years later.
Zorevunersen cuts seizures by 91% in Dravet syndrome, a rare genetic childhood epilepsy. The first disease-modifying treatment targets SCN1A mutations—a precision medicine breakthrough.
A single infusion of VERVE-102 could replace daily statins forever. Early trials show 69% LDL reduction. Here's how base editing could reshape cardiovascular medicine.
After 40 years of failed promises, spider silk is finally in mass production. Kraig Biocraft is producing 10 metric tons monthly using genetically modified silkworms.
Four astronauts launch on Artemis II this April, flying around the Moon for the first time since 1972. Meet the crew breaking new ground 53 years later.
Zorevunersen cuts seizures by 91% in Dravet syndrome, a rare genetic childhood epilepsy. The first disease-modifying treatment targets SCN1A mutations—a precision medicine breakthrough.
Apple's new Siri promises on-screen awareness and cross-app actions. But after 18 months of delays and hallucinated news summaries, can users trust it?
